Meeting
2022 ASCO Annual Meeting
Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
Authors
Erika Richtig
Department of Dermatology, Medical University of Graz, Graz, Austria
Erika Richtig , Carmen Loquai , Andrea Forschner , Ralf Gutzmer , Jessica Cecile Hassel , Jochen Utikal , Sebastian Haferkamp , Friedegund Elke Meier , Dirk Debus , Reinhard Dummer , Roger Anton Fredy Von Moos , Jan Thompson , Laura Gengenbacher , Olivier Michielin , Christoph Hoeller , Dirk Schadendorf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9526)
DOI
10.1200/JCO.2022.40.16_suppl.9526
Abstract #
9526
Poster Bd #
119
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
First Author: Erika Richtig
Poster
2019 ASCO Annual Meeting
Update on Overall Survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma.
First Author: Gabriella Liszkay
Poster
2024 ASCO Genitourinary Cancers Symposium
Safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer: Real-world evidence from a European database.
First Author: Stefanie Zschaebitz
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson